NO975585L - C-4' modifiserte adenosin-kinase inhibitorer - Google Patents

C-4' modifiserte adenosin-kinase inhibitorer

Info

Publication number: NO975585L
Authority: NO; Norway
Prior art keywords: kinase inhibitors; adenosine kinase; modified adenosine; adenosine; substituents
Prior art date: 1995-06-07

Application number

NO975585A

Other languages

English (en)

Norwegian (no)

Other versions

NO975585D0 (no

Inventor

Serge H Boyer

Mark D Erion

Bheemarao G Ugarkar

Original Assignee

Gensia Sicor

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1997-12-03

Publication date

1998-02-05

1997-12-03 Application filed by Gensia Sicor filed Critical Gensia Sicor

1997-12-03 Publication of NO975585D0 publication Critical patent/NO975585D0/no

1998-02-05 Publication of NO975585L publication Critical patent/NO975585L/no

Links

239000003121 adenosine kinase inhibitor Substances 0.000 title abstract 4
OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical class Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 title 1
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
125000001424 substituent group Chemical group 0.000 abstract 2
239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
229960005305 adenosine Drugs 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
125000003843 furanosyl group Chemical group 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
239000002777 nucleoside Substances 0.000 abstract 1
229940127073 nucleoside analogue Drugs 0.000 abstract 1
150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
239000002718 pyrimidine nucleoside Substances 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

NO975585A 1995-06-07 1997-12-03 C-4' modifiserte adenosin-kinase inhibitorer NO975585L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/486,161 US5674998A (en)	1989-09-15	1995-06-07	C-4' modified adenosine kinase inhibitors
PCT/US1996/010404 WO1996040705A1 (en)	1995-06-07	1996-06-07	C-4' modified adenosine kinase inhibitors

Publications (2)

Publication Number	Publication Date
NO975585D0 NO975585D0 (no)	1997-12-03
NO975585L true NO975585L (no)	1998-02-05

Family

ID=23930844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO975585A NO975585L (no)	1995-06-07	1997-12-03	C-4' modifiserte adenosin-kinase inhibitorer

Country Status (24)

Country	Link
US (1)	US5674998A (de)
EP (1)	EP0832091B1 (de)
JP (1)	JPH11507387A (de)
KR (1)	KR19990022740A (de)
CN (1)	CN1190401A (de)
AP (1)	AP9701165A0 (de)
AT (1)	ATE257841T1 (de)
AU (1)	AU6178396A (de)
BG (1)	BG102163A (de)
BR (1)	BR9609013A (de)
CA (1)	CA2220642A1 (de)
CZ (1)	CZ392797A3 (de)
DE (1)	DE69631330T2 (de)
EA (1)	EA199800009A1 (de)
HU (1)	HUP9802193A3 (de)
IL (1)	IL122335A0 (de)
IS (1)	IS4621A (de)
MX (1)	MX9709859A (de)
NO (1)	NO975585L (de)
OA (1)	OA10639A (de)
PL (1)	PL323904A1 (de)
SK (1)	SK166097A3 (de)
TR (1)	TR199701539T1 (de)
WO (1)	WO1996040705A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0682027B1 (de) *	1994-05-03	1997-10-15	Novartis AG	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
ATE212993T1 (de) *	1995-07-06	2002-02-15	Novartis Erfind Verwalt Gmbh	Pyrolopyrimidine und verfahren zu ihrer herstellung
US6051578A (en) *	1996-02-12	2000-04-18	Pfizer Inc.	Pyrazolopyrimidines for treatment of CNS disorders
US7863444B2 (en)	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
US6713474B2 (en)	1998-09-18	2004-03-30	Abbott Gmbh & Co. Kg	Pyrrolopyrimidines as therapeutic agents
YU25500A (sh) *	1999-05-11	2003-08-29	Pfizer Products Inc.	Postupak za sintezu analoga nukleozida
US6831069B2 (en)	1999-08-27	2004-12-14	Ribapharm Inc.	Pyrrolo[2,3-d]pyrimidine nucleoside analogs
KR20020092904A (ko) *	1999-08-27	2002-12-12	아이씨엔 파마슈티컬스, 인코포레이티드	피롤로[2,3-ｄ]피리미딘 누클레오사이드 유사체
IL148718A0 (en)	1999-09-17	2002-09-12	Abbott Gmbh & Co Kg	Pyrazolopyrimidines as therapeutic agents
US7071199B1 (en)	1999-09-17	2006-07-04	Abbott Gmbh & Cco. Kg	Kinase inhibitors as therapeutic agents
EP1250128A2 (de) *	1999-12-16	2002-10-23	Alcon, Inc.	Adenosinekinaseinhibitoren zur behandlung von schädungen des sehnervs und der retina
KR100517163B1 (ko) *	2000-02-10	2005-09-26	미쯔이카가쿠 가부시기가이샤	1-인산화 당유도체 아노머의 선택적인 제조방법 및뉴클레오사이드의 제조방법
US7638496B2 (en)	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
US7414036B2 (en) *	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
AU2002951247A0 (en)	2002-09-06	2002-09-19	Alchemia Limited	Compounds that interact with kinases
BRPI0400869B8 (pt) *	2004-03-02	2021-05-25	Univ Estadual Campinas Unicamp	novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
US9512125B2 (en)	2004-11-19	2016-12-06	The Regents Of The University Of California	Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
AU2006210422B2 (en)	2005-02-04	2012-09-13	Takeda Pharmaceutical Company Limited	Inhibitors of E1 activating enzymes
JP2009504677A (ja) *	2005-08-12	2009-02-05	メルク・エンド・カムパニー・インコーポレーテツド	新規２’−ｃ−メチル及び４’−ｃ−メチルヌクレオシド誘導体
CN106008512B (zh)	2006-02-02	2019-03-12	千禧药品公司	E1活化酶抑制剂
KR101499783B1 (ko)	2006-04-04	2015-03-09	더 리젠트스 오브 더 유니이버시티 오브 캘리포니아	키나제 길항물질
US20110160232A1 (en)	2007-10-04	2011-06-30	Pingda Ren	Certain chemical entities and therapeutic uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en) *	2008-01-04	2014-03-13	Intellikine, Llc	Certain chemical entities, compositions and methods
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
MX2011000216A (es)	2008-07-08	2011-03-29	Intellikine Inc	Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
WO2010036380A1 (en)	2008-09-26	2010-04-01	Intellikine, Inc.	Heterocyclic kinase inhibitors
WO2010045542A2 (en)	2008-10-16	2010-04-22	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (en)	2009-05-07	2010-11-11	Intellikine, Inc.	Heterocyclic compounds and uses thereof
SG10201402148SA (en)	2009-05-14	2014-07-30	Millennium Pharm Inc	Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
WO2011005860A2 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	5' phosphate mimics
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
JP5951600B2 (ja)	2010-05-21	2016-07-13	インフィニティーファーマシューティカルズ，インコーポレイテッド	キナーゼ調節のための、化合物、組成物および方法
US8901133B2 (en)	2010-11-10	2014-12-02	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20180080358A (ko)	2011-01-10	2018-07-11	인피니티 파마슈티칼스, 인코포레이티드	이소퀴놀린온 및 이의 고체 형태의 제조 방법
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
CN103930422A (zh)	2011-07-19	2014-07-16	无限药品股份有限公司	杂环化合物及其用途
EP2734530A1 (de)	2011-07-19	2014-05-28	Infinity Pharmaceuticals, Inc.	Heterocyclische verbindungen und ihre verwendung
CN103998442B (zh)	2011-08-29	2016-09-14	无限药品股份有限公司	杂环化合物及其用途
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
SG10201610936RA (en)	2011-12-22	2017-02-27	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN105732639A (zh)	2012-06-29	2016-07-06	辉瑞大药厂	作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
WO2014052669A1 (en)	2012-09-26	2014-04-03	The Regents Of The University Of California	Modulation of ire1
IL291945B2 (en)	2012-11-01	2025-11-01	Infinity Pharmaceuticals Inc	Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP3424938B1 (de)	2013-06-26	2020-07-22	Janssen BioPharma, Inc.	4'-azidoalkyl-substituierte nukleoside, nukleotide und analoga davon
MX389256B (es)	2013-10-04	2025-03-20	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
AU2014331863C1 (en)	2013-10-11	2019-05-16	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
EP3083618B1 (de)	2013-12-17	2018-02-21	Pfizer Inc	Neuartige 3,4-disubstituierte-1h-pyrrolo[2,3-b]pyridine und 4,5-disubstituierte 7h-pyrrolo[2,3-c]pyridazine als lrrk2-hemmer
EP4066834A1 (de)	2014-03-19	2022-10-05	Infinity Pharmaceuticals, Inc.	Heterocyclische verbindungen zur verwendung in der behandlung von pi3k-gamma-vermittelten erkrankungen
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3212201B1 (de)	2014-10-28	2022-10-19	BCI Pharma	Nukleosidkinaseinhibitoren
KR102630013B1 (ko)	2015-08-06	2024-01-25	키메릭스 인크.	항바이러스제로서 유용한 피롤로피리미딘 뉴클레오시드 및 그의 유사체
CN108349985A (zh)	2015-09-14	2018-07-31	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
CN108137586B (zh)	2015-09-14	2021-04-13	辉瑞大药厂	作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA3028718A1 (en)	2016-06-24	2017-12-28	Infinity Pharmaceuticals, Inc.	Combination therapies
US11111264B2 (en)	2017-09-21	2021-09-07	Chimerix, Inc.	Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
WO2021023888A1 (en)	2019-08-08	2021-02-11	B.C.I. Pharma	Isoquinoline derivatives as protein kinase inhibitors
AU2020412779A1 (en) *	2019-12-23	2022-06-23	Sanford Burnham Prebys Medical Discovery Institute	Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators and uses thereof
EP4106876B1 (de)	2020-02-18	2025-09-17	Gilead Sciences, Inc.	Antivirale verbindungen
TWI794742B (zh)	2020-02-18	2023-03-01	美商基利科學股份有限公司	抗病毒化合物
TWI874791B (zh)	2020-02-18	2025-03-01	美商基利科學股份有限公司	抗病毒化合物
KR102923359B1 (ko)	2021-04-16	2026-02-05	길리애드 사이언시즈, 인코포레이티드	아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
KR102639275B1 (ko) *	2021-06-08	2024-02-21	퓨쳐메디신 주식회사	다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물
EP4387977A1 (de)	2021-08-18	2024-06-26	Gilead Sciences, Inc.	Phospholipidverbindungen und verfahren zu ihrer herstellung und verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4455420A (en) *	1983-01-13	1984-06-19	Hoffmann-La Roche Inc.	4-Amino-7-(5-deoxy-beta-D-ribofuranosyl)-5-iodo-7H-pyrrolo[2,3-d] pyrimidine
DE3712735A1 (de) *	1987-04-15	1988-11-10	Boehringer Mannheim Gmbh	Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
FI933303L (fi) *	1991-01-23	1993-08-31	Gensia Inc	Adenosinkinasinhibitorer
WO1992012718A1 (en) *	1991-01-23	1992-08-06	Gensia, Inc.	Adenosine kinase inhibitors
AU673055B2 (en) *	1993-02-03	1996-10-24	Gensia, Inc.	Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
IL108523A0 (en) *	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US6143749A (en) *	1995-06-07	2000-11-07	Abbott Laboratories	Heterocyclic substituted cyclopentane compounds

1995
- 1995-06-07 US US08/486,161 patent/US5674998A/en not_active Expired - Fee Related
1996
- 1996-06-07 SK SK1660-97A patent/SK166097A3/sk unknown
- 1996-06-07 JP JP9502290A patent/JPH11507387A/ja not_active Ceased
- 1996-06-07 BR BR9609013-8A patent/BR9609013A/pt unknown
- 1996-06-07 KR KR1019970709182A patent/KR19990022740A/ko not_active Withdrawn
- 1996-06-07 WO PCT/US1996/010404 patent/WO1996040705A1/en not_active Ceased
- 1996-06-07 IL IL12233596A patent/IL122335A0/xx unknown
- 1996-06-07 CZ CZ973927A patent/CZ392797A3/cs unknown
- 1996-06-07 PL PL96323904A patent/PL323904A1/xx unknown
- 1996-06-07 AP APAP/P/1997/001165A patent/AP9701165A0/en unknown
- 1996-06-07 EA EA199800009A patent/EA199800009A1/ru unknown
- 1996-06-07 AT AT96919442T patent/ATE257841T1/de not_active IP Right Cessation
- 1996-06-07 AU AU61783/96A patent/AU6178396A/en not_active Abandoned
- 1996-06-07 CA CA002220642A patent/CA2220642A1/en not_active Abandoned
- 1996-06-07 HU HU9802193A patent/HUP9802193A3/hu unknown
- 1996-06-07 CN CN96195383A patent/CN1190401A/zh active Pending
- 1996-06-07 TR TR97/01539T patent/TR199701539T1/xx unknown
- 1996-06-07 DE DE69631330T patent/DE69631330T2/de not_active Expired - Fee Related
- 1996-06-07 EP EP96919442A patent/EP0832091B1/de not_active Expired - Lifetime
1997
- 1997-11-26 IS IS4621A patent/IS4621A/is unknown
- 1997-12-03 NO NO975585A patent/NO975585L/no unknown
- 1997-12-03 OA OA70150A patent/OA10639A/en unknown
- 1997-12-08 MX MX9709859A patent/MX9709859A/es unknown
1998
- 1998-01-07 BG BG102163A patent/BG102163A/xx unknown

Also Published As

Publication number	Publication date
CZ392797A3 (cs)	1999-04-14
TR199701539T1 (xx)	1998-04-21
JPH11507387A (ja)	1999-06-29
KR19990022740A (ko)	1999-03-25
IS4621A (is)	1997-11-26
EA199800009A1 (ru)	1998-06-25
SK166097A3 (en)	1999-06-11
MX9709859A (es)	1998-08-30
DE69631330T2 (de)	2004-10-28
DE69631330D1 (de)	2004-02-19
AP9701165A0 (en)	1998-01-31
BR9609013A (pt)	1999-12-14
BG102163A (en)	1998-10-30
EP0832091A1 (de)	1998-04-01
NO975585D0 (no)	1997-12-03
HUP9802193A2 (hu)	1999-05-28
IL122335A0 (en)	1998-04-05
CA2220642A1 (en)	1996-12-19
ATE257841T1 (de)	2004-01-15
WO1996040705A1 (en)	1996-12-19
HUP9802193A3 (en)	1999-10-28
PL323904A1 (en)	1998-04-27
US5674998A (en)	1997-10-07
CN1190401A (zh)	1998-08-12
AU6178396A (en)	1996-12-30
EP0832091B1 (de)	2004-01-14
OA10639A (en)	2002-09-17

Publication	Publication Date	Title
NO975585L (no)	1998-02-05	C-4' modifiserte adenosin-kinase inhibitorer
ATE296309T1 (de)	2005-06-15	Wasserlösliche adenosin kinase inhibitoren
ATE282628T1 (de)	2004-12-15	Oral aktive adenosinkinase-inhibitoren
Hao et al.	1988	Factors determining the activity of 2', 3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.
Carson et al.	1977	Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase (s)
Balzarini et al.	1987	2', 3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis.
Brink et al.	1964	Metabolism and distribution of 9-β-D-arabinofuranosyladenine in mouse tissues
Meier et al.	1999	cyclo Sal-Pronucleotides of 2 ‘-Fluoro-ara-and 2 ‘-Fluoro-ribo-2 ‘, 3 ‘-dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade
EP0653439A3 (de)	1995-10-25	Stabilisierte Oligonucleotide und deren Verwendung.
NO932289L (no)	1993-12-23	2'-deoksy-2',2'-difluor(4-substituerte pyrimidin)nukleosider med antiviralog anticanceraktivitet og mellomprodukter
CA2419399A1 (en)	2002-03-07	Nucleoside derivatives for the treatment of hepatitis c
DK468288A (da)	1989-02-23	Antivirale forbindelser
SE9502474D0 (sv)	1995-07-06	Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa
Ray	2005	Intracellular interactions between nucleos (t) ide inhibitors of HIV reverse transcriptase
Piper et al.	1982	Biochemical basis for the differential sensitivity of human T-and B-lymphocyte lines to 5-fluorouracil
Pisarev et al.	1997	Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication
DK0720604T3 (da)	1998-07-27	Konformationelt låste nukleosidanaloger
Kaufman et al.	1962	Comparison of specific antiviral agents in herpes simplex keratitis
Montgomery	1986	The design of chemotherapeutic agents
BR0016162A (pt)	2002-08-13	Composições e métodos para l-nucleosìdeos, lnucleotìdeos e seus análogos
Leoutsakos et al.	1986	The effect of adenosine and its analogues on cyclic AMP changes and histamine secretion from rat peritoneal mast cells stimulated by various ligands
Törnevik et al.	1990	2', 3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine.
EP0665016A4 (de)	1998-01-21	Mittel zum wiederherstellen der herzfunktion.
Maeda et al.	1997	Synthesis of a novel dioxane nucleoside having two bases, 2 (R)-(5-fluorouracil-1-yl)-5 (R)-hydroxymethyl-3 (R)-(uracil-1-yl)-1, 4-dioxane and its 2 (S)-isomer, from uridine
Svärd	1958	Acid-soluble nucleotides from the blood of metamorphosing salmon